
Vergent Bioscience names Adam Gridley President & CEO. John Santini, PhD, moves to CTO to lead platform expansion as we advance a Phase 3 study evaluating abenacianine for tumor visualization during lung cancer surgery. Read more: bit.ly/43kDXu7 #Leadership





